Business - Briefly   

DRL gets USFDA final nod for Fexofenadine

HYDERABAD: Dr. Reddy's Laboratories has announced that it has received final approval from the USFDA for its Abbreviated New Drug Application (ANDA) for Fexofenadine hydrochloride tablets 30 mg, 60 mg and 180 mg. Fexofenadine hydrochloride is the AB-rated generic equivalent of Sanofi-Aventis' Allegra that is indicated for symptoms associated with seasonal allergic rhinitis and treatment of uncomplicated skin manifestations of chronic idiopathic urticaria in adults and children above six years. The company will commence commercial marketing of this product immediately.

Printer friendly page  
Send this article to Friends by E-Mail

Stories in this Section

2-year deadline for cos. to fulfil public holding norms
Polaris certification centre for Belfast
Postal insurance funds likely to be invested in stock market
Maruti to buy Suzuki stake in MSAIL
Sensex drops 119 points in volatile trading
Ramco software for airlines
MSPL eyes iron ore mines in Brazil and Australia
BSE/NSE Notes
JRG Securities to expand operations
Railway division earnings go up
HMIL to increase number of dealers to 200
Factamfos sales go up: FACT
Rupee recovers against dollar
Exchange rates
Bullion rates
Inflation drops to 3.51 p.c.
Jagson Airlines sells stake
Jet's consultancy service to Sahara
TRAI on use of special characters
Orissa to cancel five MoUs for steel plants
Sharekhan receives funding
Godrej Aadhaar ties up with Apollo Pharmacy
Shapoorji Pallonji's mass housing project
K.M. Sugar Mills plans Rs. 200 crore expansion
DRL gets USFDA final nod for Fexofenadine
Joy Ghosh to head HICC marketing
DSCL offers eco-friendly door, window systems
SpiceJet's Delhi-Hyderabad-Chennai flight
Cottons by Century in Kochi
Open house on foreign trade policy
Assyst joins hands with IIE
Sadhana 2006 at SoS children's village

Copyright © 2006, The Hindu. Republication or redissemination of the contents of this screen are expressly prohibited without the written consent of The Hindu